Key Drivers
- No Revenue
- Negative Equity
- Heavy Dilution
AIAI Summary
ACHV is now a manufacturing-remediation and launch-financing trade—not a clinical-efficacy bet—so investors should watch for a credible FDA resubmission path toward potential 2027 approval while discounting upside for substantial existing and potential warrant dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •No Revenue
- •Negative Equity
- •Heavy Dilution
ACHV's stronger cash and investment base is offset by no revenue, escalating losses, negative equity, liquidity pressure, and heavy shareholder dilution, indicating significant financial risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term rebound
- •Range-bound trading
- •Key breakout zone
ACHV has rebounded above its last-month average, but remains neutral unless it breaks $8.49 resistance or loses $7.06 support.
Sharp rebound from $7.06 on 2026-09-11 to $7.98 on 2026-09-18
Sentiment & News
Key News Insights:
- •Frazier major stake
- •Deutsche Bank entry
- •Employee equity awards
Achieve Life Sciences gained strong institutional backing led by Frazier's $49.7M stake, while new employee equity awards support continued growth.
The substantial institutional buying is a positive signal for investor confidence in Achieve's outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings